David Horowitz

David’s practice focuses on pharmaceutical compliance issues, including Current Good Manufacturing Practice (CGMP), inspections, recalls, post-market reporting, import/export, drug supply chain security, pharmacy issues, and OTC drug issues.  During his time at HHS and FDA, David developed a deep understanding of the institutions, organizational structures, procedures, and cultures through which regulatory policy and compliance decisions are considered, developed, and implemented across all branches of government.  The combination of his deep technical knowledge and years of experience allows David to provide strategic and tactical advice to proactively avoid regulatory problems, as well as respond effectively to unanticipated challenges.

As Deputy General Counsel at HHS (2010-2017), David oversaw and coordinated legal services in support of FDA and other HHS public health agencies. His work focused on FDA regulatory policy and compliance-related issues. During his tenure at FDA – which included five years as head of the Office of Compliance for drugs, and three years as Assistant Commissioner for Compliance Policy – David played a leadership role in numerous major initiatives, including the modernization of FDA's approach to pharmaceutical manufacturing quality and the agency's efforts to develop and implement a more scientific, risk-based approach to inspection and enforcement.  He also led the development of FDA’s first risk-based quantitative model used to prioritize drug manufacturing inspections.